Research programme: vascular disrupting agents - Angiogene Pharmaceuticals

Drug Profile

Research programme: vascular disrupting agents - Angiogene Pharmaceuticals

Alternative Names: ANG-501; ANG500 series

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Angiogene Pharmaceuticals
  • Class
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jun 2016 OXiGENE is now called Mateon Therapeutics
  • 21 Jun 2012 Programme licensed to OXiGENE worldwide for the treatment of Carcinoid syndrome
  • 07 Jan 2011 Research programme: vasculature targeting agents - Angiogene Pharmaceuticals is available for licensing as of 07 Jan 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top